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ABSTRACT
Objective Hepatocellular carcinoma (HCC) is a
heterogeneous tumour displaying a complex variety of
genetic and epigenetic changes. In human cancers,
aberrant post-transcriptional modiﬁcations, such as
alternative splicing and RNA editing, may lead to tumour
speciﬁc transcriptome diversity.
Design By utilising large scale transcriptome
sequencing of three paired HCC clinical specimens and
their adjacent non-tumour (NT) tissue counterparts at
depth, we discovered an average of 20 007 inferred A to
I (adenosine to inosine) RNA editing events in
transcripts. The roles of the double stranded RNA
speciﬁc ADAR (Adenosine DeAminase that act on RNA)
family members (ADARs) and the altered gene speciﬁc
editing patterns were investigated in clinical specimens,
cell models and mice.
Results HCC displays a severely disrupted A to I RNA
editing balance. ADAR1 and ADAR2 manipulate the A
to I imbalance of HCC via their differential expression in
HCC compared with NT liver tissues. Patients with
ADAR1 overexpression and ADAR2 downregulation in
tumours demonstrated an increased risk of liver cirrhosis
and postoperative recurrence and had poor prognoses.
Due to the differentially expressed ADAR1 and ADAR2
in tumours, the altered gene speciﬁc editing activities,
which was reﬂected by the hyper-editing of FLNB
(ﬁlamin B, β) and the hypo-editing of COPA (coatomer
protein complex, subunit α), are closely associated with
HCC pathogenesis. In vitro and in vivo functional assays
prove that ADAR1 functions as an oncogene while
ADAR2 has tumour suppressive ability in HCC.
Conclusions These ﬁndings highlight the fact that the
differentially expressed ADARs in tumours, which are
responsible for an A to I editing imbalance, has great
prognostic value and diagnostic potential for HCC.
INTRODUCTION
RNA editing is an integral step in generating the
diversity and plasticity of cellular RNA signatures.
The best characterised type of RNA editing found
in mammals converts C to U (cytosine to uracil)
and A to I (adenosine to inosine). In humans, the
most frequent type of editing is the conversion of
A to I, which is catalysed by the double stranded
RNA (dsRNA) speciﬁc ADAR (Adenosine
DeAminase that act on RNA) family of proteins.
Because the translation machinery reads inosine as
guanosine (G), the ADARs may recode transcripts,
which results in a proteome that is divergent from
the genome1–4 and thus modulates the protein
sequence and function of several gene products.
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Signiﬁcance of this study
What is already known about this subject?
▸ RNA editing is a widespread post-
transcriptional process contributing to greater
cellular transcriptome diversity in eukaryotes.
▸ In humans, the most frequent type of editing is
the conversion of A to I, which is catalysed by
the dsRNA speciﬁc ADAR family of RNA editing
enzymes.
▸ Until now, only a few recoding RNA editing
events (eg, Q/R site editing in the glutamate
receptor) have been veriﬁed, and no apparent
causal relationship between altered RNA
editing levels and cancer progression exists.
▸ Accumulating evidence has indicated that a
hypo-editing (editing deﬁciency) phenotype is
found in brain tumours and tumour tissues,
such as prostate, lung, kidney and testis, and
the hypo-editing phenotype is linked to several
cancer phenotypes in paediatric astrocytomas
and malignant gliomas. It has also been
reported that a gene speciﬁc hyper-editing
phenotype is found in metastatic lobular breast
cancer and acute myeloid leukaemia.
What are the new ﬁndings?
▸ We provide the ﬁrst extensive analysis of RNA
editing in the human liver cancer transcriptome.
▸ HCC, distinct from most cancer types, is neither
a hypo- nor a hyper-editing cancer; instead,
HCC displays a severely disrupted A to I RNA
editing balance induced by the differentially
expressed ADARs (ADAR1 and ADAR2).
▸ Clinically, the differentially expressed ADARs,
which are characterised by ADAR1
overexpression and ADAR2 downregulation in
tumours, have great prognostic value and
diagnostic potential for HCC.
▸ ADAR1 has oncogenic ability while ADAR2
functions as a tumour suppressor in HCC.
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Editing of a speciﬁc adenosine is rarely 100% efﬁcient; conse-
quently, the ADARs can generate different protein isoforms in
the same cell. Due to the diverse impact of RNA editing on
gene expression and function, it is possible that the misregula-
tion of RNA editing may play a role in tumorigenesis by either
inactivating tumour suppressor or activating genes that promote
tumour progression.
Hepatocellular carcinoma (HCC) is one of the most common
types of cancer; it is the third most common cause of cancer
related deaths worldwide and it is associated with a poor clinical
outcome.5 Furthermore, the incidence of HCC is continually
increasing in the USA and Western Europe.6 As with many other
solid tumours, HCC development is believed to be a multistep
process involving the accumulation of genetic and epigenetic
alterations.7 8 The recent advent of RNA sequencing (RNA-Seq)
has provided a powerful tool that can be used to study changes
in transcriptomes and genomes.9–11 In this study, we used
RNA-Seq to identify post-transcriptional editing events in three
matched pairs of patient derived HCC clinical specimens and
their adjacent non-tumour (NT) liver tissue counterparts. We
identiﬁed an average of 20 007 inferred A to I RNA editing
events in non-coding genes and introns, untranslated regions
(UTRs) and coding regions of protein coding genes. Because the
editing sites occur in coding regions and may result in amino
acid substitutions affecting protein properties and interactions,
we were particularly interested in the identiﬁcation and charac-
terisation of RNA editing events within coding regions; these
events may be involved or responsible for HCC initiation and
progression. Our recent study has reported that the hyper-
editing of a gene called antizyme inhibitor 1 (AZIN1) predis-
poses to human HCC.12 In this study, we performed an exten-
sive analysis of RNA editing in the human liver cancer
transcriptome and demonstrated that RNA editing differs
between HCC and matched NT liver tissues as follows: (1)
unlike most cancer types, HCC displays a disrupted A to I RNA
editing balance that is characterised by gene speciﬁc
hypo-editing and hyper-editing; (2) ADAR1 and ADAR2 but not
ADAR3 are responsible for the disrupted editing balance in
HCC through their differential expression in HCC compared
with NT liver tissues; (3) patients with ADAR1 overexpression
and ADAR2 downregulation in tumours demonstrated an
increased risk of liver cirrhosis and postoperative recurrence and
had poor prognoses; (4) speciﬁc recoding events in two genes,
FLNB (ﬁlamin B, β) and COPA (coatomer protein complex,
subunit α) which display the altered editing patterns in tumours
compared with normal tissues; and (5) ADAR1 has an
oncogenic ability while ADAR2 functions as a tumour suppres-
sor in HCC.
MATERIALS AND METHODS
Detailed methods are included in the online supplementary
materials and methods.
Clinical samples
Guangzhou cohort
A total of 125 paired human HCC and adjacent NT tissues that
were surgically removed, snap frozen in liquid nitrogen (for
protein, RNA and DNA extraction) and embedded in a parafﬁn
block (for tissue microarray construction) were obtained from
the Sun Yat-Sen University Cancer Centre (Guangzhou, China),
along with their associated clinicopathological summaries,
between 2002 and 2007.
Shanghai cohort
A total of 46 paired human HCC and matched NT specimens
were obtained from the hepatectomy specimen archives at the
Eastern Hepatobiliary Surgery Hospital (Shanghai, China).
None of these patients received preoperative chemotherapy or
radiotherapy.
Healthy human liver tissues were obtained from donor livers
that had not been used for transplantation; the tissues were pro-
vided by Dr Man K and Dr Lo CM (Department of Surgery,
University of Hong Kong). All of the samples were immediately
frozen in liquid nitrogen or ﬁxed in 10% formalin for parafﬁn
embedding. All of the patients provided written informed con-
sents for the use of their clinical specimens for medical research.
All of the samples used in this study were approved by the com-
mittees for ethics review for research involving human subjects
at Sun Yat-Sen University, University of Hong Kong and
National University of Singapore.
Cell lines
The SNU-423, 449, 475, 182, 387 and 398 cell lines were
obtained from the American Type Culture Collection. All of
these cells were maintained in RPMI medium (Gibco BRL,
Grand Island, New York, USA) supplemented with 10% fetal
bovine serum (Gibco BRL). All of the cell lines used in this
study were regularly authenticated by morphological observa-
tion and tested for mycoplasma contamination (MycoAlert,
Lonza Rockland, Rockland, Maine, USA). The cells were incu-
bated at 37°C in a humidiﬁed incubator containing 5% CO2.
Discovery of RNA editing sites
Brieﬂy, aligned ﬁles were processed with SAMtools and subse-
quently VarScan (V.2.2)13 for the detection of A to G (positive
strand) or T to C (negative strand) substitutions. Variance calling
was constrained to locations within gene regions containing at
least 10× coverage, a variation frequency of greater than 10%
and a base quality of more than 15. We ﬁrst ﬁltered the editing
sites against the known sites in the NCBI dbSNP database (Build
135) to eliminate germline variants. Second, we eliminated
single nucleotide variations (SNVs) for which more than two
types of nucleotide sequences were found because these likely
represent false positives. Finally, we excluded polymorphic sites
with a variation frequency of 100% because they may have
resulted from intrinsic mapping errors. After validation, the
false positive rate of RNA editing site detection was approxi-
mately 40%.
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ These ﬁndings suggest a widespread occurrence of transcript
variation at the single nucleotide level in the human liver
transcriptome and highlight a link between the RNA editome
imbalance in the forms of defective and excess gene speciﬁc
RNA editing activity to HCC pathogenesis. Monitoring
expression levels of ADARs or the global activity of RNA
editing represents a useful early biomarker than can be
utilised to detect disorders in HCC even before clinical
symptoms become apparent.
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Analysis of RNA editing
Direct sequencing was performed on PCR products, and editing
was calculated with the Discovery Studio Gene (DSGene) 1.5
programme (Accelrys Inc, San Diego, California, USA). The reli-
ability of this method was further veriﬁed by cloning of individ-
ual sequences. PCR products were subcloned into the T-easy
vector (Promega), and approximately 50 individual plasmids
were sequenced for each sample. The percentage of edited
clones was determined and compared with the DSGene quantiﬁ-
cation. For each sample, 2–3 independent RT-PCR reactions
were performed.
Statistical analyses
Unless otherwise indicated, the data are presented as the mean
±SD of three independent experiments. The SPSS statistical
package for Windows (V.16; SPSS) was used to perform the data
analyses. The clinicopathological features of patients with a dif-
ferent status for the differential expression of ADAR1 and
ADAR2 were compared using a non-parametric crosstabs ana-
lysis (χ2 test) for categorical variables. ADAR1 or ADAR2 expres-
sion levels in any two groups of clinical samples (eg, tumours
and matched NT liver tissues) were compared using the Mann–
Whitney U test. Kaplan–Meier plots and log rank tests were
used for disease free survival (DFS) analysis. DFS times were
calculated from the data of curative surgery to HCC recurrence,
death or the last follow-up data. For the tissue microarray
(TMA) analysis, which was based on immunohistochemical
(IHC) scores, ADAR1 expression levels in the primary HCC
tissues and their matched NT liver tissues were compared using
a Wilcoxon signed rank test. A paired Student’s t test was used
to compare editing levels of FLNB or COPA in HCC and
matched NT liver specimens of patients from the Guangzhou
(GZ) and Shanghai (SH) cohorts. Editing levels of FLNB and
COPA between two preselected groups were compared using
the Mann–Whitney U test. An unpaired two tailed Student’s t
test was used to compare the number of foci, number of migra-
tive and invasive cells, tumour volume and the relative expres-
sions of target genes between any two preselected groups.
A p value of <0.05 was considered to be statistically signiﬁcant.
RESULTS
Global identiﬁcation of potential A to I editing sites
by RNA-Seq
The high throughput transcriptome sequencing (RNA-Seq) of
three pairs of primary HCC and matched NT liver tissues
(HCC448N/T, HCC473N/T and HCC510N/T) from HCC
patients of Chinese origin (GZ cohort) generated 132.3 million
reads that could be uniquely aligned to the human genome
(hg19). The aligned reads provided substantial coverage (an
average of 83.03%) for the vast majority of the identiﬁed
mRNA transcripts.12 The global identiﬁcation of potential A to
I (G) editing sites was called using VarScan,13 with the following
parameters: a minimum coverage depth of 10, a variation fre-
quency of more than 10% and a base quality of more than 15
(ﬁgure 1A). To facilitate the detection of actual A to I (G)
editing events, we ﬁrst ﬁltered the editing sites against known
events in the NCBI dbSNP database (Build 135) to eliminate
germline variants. Next, we eliminated SNVs for which more
than two types of nucleotide sequence were found because they
likely represented false positives. Finally, we excluded poly-
morphic sites with a variation frequency of 100% because they
may have resulted from an intrinsic mapping error. The distribu-
tion of the remaining editing sites in each functional category
(coding sequence, UTR, intron, splicing sites, intergenic region
and pseudo/ncRNA) is shown in ﬁgure 1B and in online supple-
mentary table S1. The majority (approximately 80%) of the
inferred editing sites in each of the samples had a low editing
level, which ranged from 0% to 20% (see online supplementary
ﬁgure S1A). Functional enrichment analysis was performed on
the genes edited in all three tumours or three NT liver speci-
mens. In both NT liver and tumour samples, the edited genes
were found to be most signiﬁcantly enriched with acute inﬂam-
matory response, metabolic process, protein processing and
response to wound (see online supplementary tables S2 and S3).
To experimentally validate our calls, we veriﬁed a subset of
potential sites by performing Sanger sequencing of both DNA
and RNA from the same samples that were utilised for
RNA-Seq. We validated 30 inferred editing sites, and the major-
ity (21/30, 70%) were veriﬁed (see online supplementary ﬁgure
S1B). Notably, UTP14C mRNA contains previously undescribed
A to G substitution at multiple sites (ﬁgure 1C). We also com-
pared sites identiﬁed in this study with editing sites in the
DARNED database14 and a human B cell dataset.15 An example
of an editing target, FLNB, exhibited conﬁrmed, extensive, non-
synonymous editing at the same site as in the human B cell
dataset. However, no transcript alteration was identiﬁed at the
position described in the DARNED database (ﬁgure 1D). These
results support the current notion that RNA editing frequency
can be regulated in a tissue or cell type speciﬁc manner.16
HCC displays a disrupted editing balance
To better understand the link between the RNA editing process
and hepatocarcinogenesis, we applied several adjustments and
additional ﬁlters to facilitate the identiﬁcation of editing sites
within coding regions that may have highly tumour suppressive
or oncogenic potentials. When the coverage depth was not less
than 15, the editing sites in the coding regions detected in more
than one NT liver but not in HCC tissues were assigned to the
‘NT speciﬁc editing’ category (ﬁgure 1E and see online supple-
mentary table S4); conversely, those sites found in more than
one tumour tissue but not in NT liver specimens were placed in
the ‘tumour speciﬁc editing’ category (ﬁgure 1E and see online
supplementary table S5). The editing sites that were found in
more than one pair of HCC and matched NT liver tissues were
placed in the ‘common editing events’ category (ﬁgure 1E and
see online supplementary table S6). Interestingly, two recoding
editing sites in AZIN112 and FLNB, which are in the ‘common
editing events’ category, demonstrated higher A to I (G) editing
frequencies in HCC448T and HCC473T than in HCC448N
and HCC473N, respectively (ﬁgure 1F and online supplemen-
tary ﬁgure S2). As a member of the ‘NT speciﬁc editing’ cat-
egory, an A to I (G) editing site at codon 164 (Ile→Val) of the
COPA gene was completely absent in all three tumour samples
(ﬁgure 1F and see online supplementary ﬁgure S2). Conversely,
a ‘tumour speciﬁc’ editing site within the UTP14C coding
region only exhibited an A to G substitution in the tumour
samples (ﬁgure 1F and see online supplementary ﬁgure S2).
These results suggest that HCC is neither a hypo-editing nor a
hyper-editing cancer; instead, HCC displayed a severely dis-
rupted A to I RNA editing balance.
In the past few years, bioinformatic and experimental studies
have revealed that the A to I editing events occur in non-coding
repetitive sequences, mostly Alu elements, and tend to undergo
multi-editing in tight clusters.17 To date, it is commonly
accepted that a reduced A to I editing in general may be
involved in the pathogenesis of cancer, and a signiﬁcant global
hypo-editing of Alu repetitive elements was observed in brain,
834 Chan THM, et al. Gut 2014;63:832–843. doi:10.1136/gutjnl-2012-304037
Hepatology
prostate, lung, kidney and testis tumours.17 In our study, the
numbers of potential A to I (G) editing sites within the Alu
sequences in three tumours were higher than their correspond-
ing NT liver samples (see online supplementary ﬁgure S3A).
We validated 30 editing sites within Alu sequences and all were
veriﬁed. The editing levels of two editing sites within the Alu
repetitive element of the gene TTPA (tocopherol (α) transfer
protein) were dramatically decreased in tumour samples (see
Figure 1 Global identiﬁcation of potential A to I (G) editing sites by RNA sequencing (RNA-Seq). (A) Distribution of potential editing sites across
all of the chromosomes (shown by exterior circle) in three paired hepatocellular carcinoma (HCC) and matched non-tumour (NT) liver samples
(HCC448N/T, HCC473N/T and HCC510N/T). The green and purple blocks in the inner circles (deep gray) indicate the A to G substitutions in the
tumour and matched NT liver samples, respectively. The green and purple blocks in the inner circle (light gray) indicate the T to C substitutions in
the tumour and matched NT liver samples, respectively. UTR, untranslated region. (B) Number of editing sites distributed in each functional category.
(C) One example of the UTP14C gene with multiple edits. The RNA editing sites identiﬁed from the RNA-Seq data are highlighted by the red boxes.
(D) Sequences of individual reads were aligned to the published human genomic sequence of the FLNB (ﬁlamin B, β) gene. An A to G conversion
was found in the HCC473T sample. The editing and reference events are highlighted by yellow shading. The green boxes denote the editing site
reported by DARNED.14 A sequence logo representation of the editing event in the tumour sample is shown below. The height of each letter is
proportional to its frequency. (E) Venn diagram illustrating the numbers of exonic editing events which were classiﬁed into the three indicated
categories. (F) Sequence chromatograms of the AZIN1, FLNB, COPA and UTP14C transcripts in the indicated tumour and matched NT liver samples.
An arrow indicates the editing position. The sequence chromatograms of the matching genomic DNA (gDNA) sequences of each gene are shown in
online supplementary ﬁgure S2.
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online supplementary ﬁgure S3B). In contrast, ﬁve editing sites in
Alu sequences of two genes called MAGT1 (magnesium trans-
porter 1) and PAICS (phosphoribosylaminoimidazole carboxylase,
phosphoribosylaminoimidazole succinocarboxamide synthetase)
were highly edited in tumour samples (see online supplementary
ﬁgure S3B). All of these data suggest that there is a disrupted A to I
editing balance in coding regions and non-coding Alu repetitive
elements in human HCC.
Differentially expressed RNA editing enzyme ADAR1 and
ADAR2 in HCC
A to I RNA editing is a post-transcriptional modiﬁcation in stem
loop structures within precursor mRNA, which is catalysed by
dsRNA speciﬁc ADAR enzymes.18 In humans, the ADAR family
is composed of three independent genes, ADAR1–3. ADAR1 and
ADAR2 are expressed in many tissues whereas ADAR3 is specif-
ically expressed in the brain.3 As described previously, RNA-Seq
proﬁling of the ADARs indicated that two ADAR1 transcript var-
iants (NM_001025107 and NM_015840) encoding 110 kDa
(p110) and 150 kDa (p150) isoforms, respectively, demonstrated
relatively high abundances in liver tissue.12 However, ADAR2
and ADAR3 were expressed at extremely low levels and were
undetectable in all samples.12 In this study, we constructed a
panel of TMAs consisting of 92 surgically resected primary
HCCs and their matched NT liver tissues from the GZ cohort.
By performing IHC staining, we observed the differential nuclear
expression of ADAR1 between the primary HCC and matched
NT liver tissues. A detailed analysis of the IHC data revealed the
ADAR1 was overexpressed in 71.7% (66/92) of the analysed
HCC tissues (p<0.001, Wilcoxon signed rank test) (ﬁgure 2A
and see online supplementary table S7). However, it was found
that the sensitivity of IHC was too low to detect ADAR2 expres-
sion in both the primary HCC and matched NT liver tissues.
Therefore, we determined expression of ADAR2 and ADAR1
Figure 2 Differential expression of ADAR (Adenosine DeAminase that acts on RNA) 1 and ADAR2 in hepatocellular carcinoma (HCC) and its
clinical implication. (A) Example of ADAR1 expression level detected in a primary HCC tumour and its matched non-tumour (NT) liver specimen.
Based on staining intensities, ADAR1 immunoreactivities were scored as strong expression (3) and weak (1) expression in the primary HCC and
matched NT liver specimens, respectively (see the online supplementary materials and methods section for details). The boxed regions are magniﬁed
and displayed in the lower panels. (B) Western blot analyses of ADAR1 and ADAR2 expression levels in ﬁve paired HCC and matched NT liver
specimens. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (C) Dot plots represent relative ADAR1 (left) and
ADAR2 (right) expression levels in HCC and corresponding NT liver tissue samples, as detected by quantitative real time PCR (mean±SD, n=92;
Mann–Whitney U test). (D) Association between the postoperative recurrence rate and status of expression of ADARs (p=0.004, χ2 test).
(E) Kaplan–Meier plots for disease free survival rate of patients demonstrating ADAR1 overexpression (OE) and ADAR2 downregulation (DR) (red
line; n=39), ADAR1 OE or ADAR2 DR (green line; n=44) and normal ADAR1 and ADAR2 expression in tumours (blue line; n=23) (log rank test).
836 Chan THM, et al. Gut 2014;63:832–843. doi:10.1136/gutjnl-2012-304037
Hepatology
using a western blot analysis and found that ADAR2 expression
in approximately 50% (15/30) of the HCC samples was lower
than in the matched NT liver specimens (ﬁgure 2B). Consistently,
ADAR1 protein expression (both p110 and p150 isoforms) in
approximately 73% (22/30) of the HCC specimens was higher
than in the matched NT liver specimens (ﬁgure 2B). In order to
obtain the expression levels of both ADAR1 and ADAR2 in all
92 paired HCCs and their matched NT liver tissues, we subse-
quently used quantitative real time PCR to examine ADAR1 and
ADAR2 expression in 92 paired specimens that were utilised for
TMA construction. As a result, ADAR1 was signiﬁcantly overex-
pressed in the HCC specimens compared with the NT liver speci-
mens (p<0.0001, Mann-Whitney U test) (ﬁgure 2C). However,
ADAR2 expression was obviously decreased in approximately
47% (43/92) of the tumour samples compared with the NT
samples (p=0.14, Mann-Whitney U test) (ﬁgure 2C).
Based on the quantitative real time PCR analysis of
ADAR1and ADAR2 expression, patients with ADAR1 overex-
pression (deﬁned as a twofold increase in ADAR1 expression in
tumours) and ADAR2 downregulation (deﬁned as a twofold
decrease in ADAR2 expression in tumours), demonstrated
higher incidences of tumour recurrence (p=0.004) and liver cir-
rhosis (p=0.016) and shorter DFS times (p = 0.003) than
patients who had ADAR1 overexpression or ADAR2 downregu-
lation and patients who had neither ADAR1 overexpression nor
ADAR2 downregulation (ﬁgure 2D, E and table 1). In the uni-
variate Cox analyses, the statistically signiﬁcant predictors for a
patient’s DFS were liver cirrhosis, American Joint Committee
on Cancer tumour staging and the differentially expressed
ADARs in tumours (see online supplementary table S8). In the
multivariate Cox analyses, differentially expressed ADARs in
tumours were shown to be an independent prognostic factor for
DFS (p=0.025, HR 1.725; 95% CI 1.071 to 2.777; see online
supplementary table S8). We conclude that the differentially
expressed ADAR1 and ADAR2 in HCC, as shown by ADAR1
overexpression and ADAR2 downregulation in tumours, pre-
dicts a poor prognosis for HCC patients.
Differentially expressed ADARs contribute to the altered
gene speciﬁc editing patterns in HCC
Due to the differentially expressed ADARs, the A to I editing
balance could be disrupted in HCC. In this study, we were
Table 1 Clinicopathological analyses of the differentially expressed ADARs in the Guangzhou cohort of 92 primary hepatocellular carcinoma
patients
Clinical feature No
Normal ADAR1 and
ADAR2 expression (n=18)†
ADAR1 OE or ADAR2
DR (n=34)‡
ADAR1 OE and ADAR2
DR (n=40)§ p Value
Gender (n (%))
Female 19 5 (27.8) 3 (8.9) 11 (27.5)
Male 73 13 (72.2) 31 (91.2) 29 (72.5) 0.073
Age (years) (n (%))
≦60 74 12 (66.7) 29 (85.3) 33 (82.5)
>60 18 6 (33.3) 5 (14.7) 7 (17.5) 0.305
HbsAg¶ (n (%))
Negative 18 6 (33.3) 6 (19.4) 6 (15.4)
Positive 70 12 (66.7) 25 (80.6) 33 (84.6) 0.290
Serum AFP (ng/mL)¶ (n (%))
≤400 52 11 (64.7) 22 (71.0) 19 (48.7)
>400 35 6 (35.3) 9 (29.0) 20 (51.3) 0.152
Tumour size (cm)¶ (n (%))
≦5 23 4 (22.2) 6 (19.4) 13 (32.5)
>5 66 14 (77.8) 25 (80.6) 27 (67.5) 0.421
Cirrhosis¶ (n (%))
Absent 26 10 (55.6) 9 (30.0) 7 (17.9)
Present 61 8 (44.4) 21 (70.0) 32 (82.1) 0.016*
Cell differentiation¶ (n (%))
Well differentiated (I–II) 17 4 (25.0) 4 (13.8) 9 (24.3)
Moderately differentiated (III) 48 7 (43.8) 19 (65.5) 22 (59.5)
Poorly differentiated (IV) 17 5 (31.3) 6 (20.7) 6 (16.2) 0.540
Recurrence or metastasis (n (%))
Absent 47 13 (72.2) 21 (61.8) 13 (32.5)
Present 45 5 (27.8) 13 (38.2) 27 (67.5) 0.004*
Tumour stage (AJCC)¶ (n (%))
Stage I 60 14 (82.4) 21 (70.0) 25 (62.5)
Stage II 20 3 (17.6) 8 (26.7) 9 (22.5)
Stage III 7 0 (0) 1 (3.3) 6 (15.0) 0.224
Mean DFS (months) 68.6 (48.3–89.0) 52.6 (39.0–66.3) 30.1 (19.3–40.9) 0.003*
*Statistical significance (p<0.05).
†Cases fitting neither of these two criteria are regarded as ‘Normal ADAR1 and ADAR2 expression’: (1) a twofold increase in ADAR1 expression level in tumours; (2) a twofold decrease
in ADAR2 expression level in tumours compared with their matched non-tumour liver samples.
‡Cases fitting either one of the two criteria listed above are defined as ‘ADAR1 OE or ADAR2 DR’ (OE, overexpression; DR, downregulation).
§Cases fitting both criteria, as listed above, are classified as ‘ADAR1 OE and ADAR2 DR’ (OE, overexpression; DR, downregulation).
¶Partial data are not available and statistics were based on available data.
ADARs, Adenosine DeAminases that act on RNA; AFP, α fetoprotein; AJCC, American Joint Committee on Cancer; DFS, disease free survival time; HbsAg, hepatitis B surface antigen.
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particularly interested in two exemplary editing targets, FLNB
and COPA. To clarify which ADARs are responsible for FLNB
and COPA editing, the tumour samples were divided into ‘high
level’ and ‘low level’ groups based on the average relative quan-
tiﬁcation (RQ) values of ADAR1 or ADAR2 in all 92 tumour
specimens (Avg[ADAR1]: 5.84; Avg[ADAR2]: 4.98). Tumours with
‘high level’ ADAR1 expression (RQ≥5.84) demonstrated a sig-
niﬁcantly higher editing level of FLNB (p=0.003) but not
COPA (p=0.81; Mann–Whitney U test) (ﬁgure 3A). Tumours
with ‘high level’ ADAR2 expression (RQ≥4.98) were found to
have higher editing degrees of both COPA (p=0.013) and
FLNB (p=0.091; Mann–Whitney U test) (ﬁgure 3B). The
Figure 3 FLNB (ﬁlamin B, β) editing is catalysed by both ADAR (Adenosine DeAminase that acts on RNA) 1 and ADAR2, while COPA (coatomer
protein complex, subunit α) editing is speciﬁcally catalysed by ADAR2. (A, B) FLNB and COPA editing level in tumours with ‘high level’ and ‘low
level’ expression of ADAR1 (A) or ADAR2 (B). The data are presented as box plots with median (horizontal line), 25–75% (box) and 5–95% (error
bar) percentiles for each group. The mean is indicated as ‘+’ (Mann–Whitney U test) and the dots indicate the outliers. (C, D) Left: Western blot
analyses of ADAR1 and ADAR2 expression in SNU-423 cells that were transiently transfected with an ADAR1 p110 variant expression construct
(ADAR1 p110) or empty vector (CTL) (C) or SNU-423 cells that were transiently transfected with an ADAR2 expression construct (ADAR2) or empty
vector (CTL) (D). (C, D) Right: sequence chromatograms of the FLNB and COPA transcripts in the indicated cell lines. The percentages of edited FLNB
or COPA transcripts were detected as described in the Materials and Methods section. An arrow indicates the editing position. (E, F) Following
transfection with the indicated constructs into SNU-423 cells that stably expressed the ADAR1 p110 isoform (E) or ADAR2 (F) (see the online
supplementary materials and methods section for details), ADAR1 and ADAR2 expression levels were detected by western blot analysis. (G) Editing
levels of FLNB and COPA in each cell line as indicated are shown in a bar chart (mean±SD of three independent experiments; *undetectable).
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ADAR1 p150 isoform is presumably responsible for the A to I
editing of viral RNAs produced by viruses18 19 but not of the
nuclear pre-mRNAs.20 To directly determine whether ADARs
regulate FLNB and COPA editing, either the ADAR1 p110
isoform or ADAR2 was overexpressed in the HCC cell line
SNU-423. SNU-423 cells overexpressing ADAR1 p110 dis-
played enhanced FLNB editing whereas ADAR1 overexpression
did not affect COPA editing (ﬁgure 3C). The introduction of
ADAR2 into SNU-423 cells resulted in increased COPA and
FLNB editing levels (ﬁgure 3D). To further conﬁrm our ﬁnd-
ings, we conducted knockdown/rescue experiments with
SNU-423 cells that stably expressed ADAR1 p110 (423-AR1) or
ADAR2 (423-AR2). Silencing of ADAR1 expression using a
small hairpin RNA (shRNA) against ADAR1 (shADAR1) in
423-AR1 cells dramatically decreased the FLNB editing level
from 27.4% to 8.2%; this editing was effectively rescued by
overexpressing an ADAR1 p110 mutant that preserves the native
amino acid sequence but contains six point mutations within
the ADAR1 shRNA targeting site (ﬁgure 3E,G). Using the same
strategy, ADAR2 knockdown in 423-AR2 cell lines dramatically
decreased the editing levels of both FLNB and COPA, and the
editing was effectively abolished by reintroducing the ADAR2
mutant into 423-AR2 cells (ﬁgure 3F, G). Together, these results
likely suggest that the differential expression of ADAR1 and
ADAR2 in tumours, which is tightly associated with the altered
gene speciﬁc editing pattern, may explain the A to I editing
imbalance in HCC.
To further investigate the relationship between RNA editing
and HCC progression, we also examined the editing frequencies
of two editing targets, FLNB and COPA, in healthy human liver
tissues (n=8) and two different cohorts of primary HCC and
NT liver samples from GZ (n=125) and SH (n=47) cohorts.
Two individual cohorts of HCC and matched NT liver samples
demonstrated dramatically higher FLNB editing degrees com-
pared with the healthy liver specimens (ﬁgure 4A). COPA
editing levels were remarkably lower in both the HCC and
matched NT liver specimens from two cohorts than those in the
healthy liver specimens (ﬁgure 4B). Moreover, two individual
cohorts of HCC samples displayed signiﬁcantly higher and
lower editing levels of FLNB and COPA, respectively, compared
with the matched NT liver tissues (FLNB: pGZ<0.0001,
pSH<0.0001; COPA: pGZ<0.0001, pSH<0.0001; Mann–
Whitney U test) (ﬁgure 4A,B). All of these data suggest that the
altered gene speciﬁc editing activities are closely associated with
HCC pathogenesis from normal to adjacent non-tumour to clin-
ically veriﬁed HCC.
Because the average FLNB or COPA editing level was
approximately 10% different between the NT liver and tumour
specimens in the GZ cohort (FLNB: 18.9 vs 31.6%; COPA:
20.7 vs 7.1%), we set an increase of not less than 10% of the
Figure 4 Altered gene speciﬁc editing patterns induced by the differentially expressed ADARs (Adenosine DeAminases that act on RNA) is closely
associated with hepatocellular carcinoma (HCC) pathogenesis. (A, B) Dot plots represent FLNB (ﬁlamin B, β) (A) and COPA (coatomer protein
complex, subunit α) (B) editing levels in healthy human liver tissues (mean±SD, n=8) and in 125 matched primary HCC and non-tumour (NT) liver
samples in the Guangzhou (GZ) cohort and in 47 matched primary HCC and NT liver samples in the Shanghai (SH) cohort (Mann–Whitney U test).
(C, D) FLNB (C) and COPA (D) editing levels in HCC and matched NT liver specimens from 125 and 47 patients in the GZ and SH cohorts (paired
Student’s t test).
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FLNB editing level in tumour tissues when compared with NT
liver tissues as the cut-off value for FLNB hyper-editing to sub-
divide HCC patients. Similarly, a decrease of not less than 10%
of the COPA editing level in tumour tissues when compared
with NT liver samples was used as the cut-off value for COPA
hypo-editing. In the GZ cohort, approximately 52% (65/125)
and 67% (84/125) of the HCC specimens displayed FLNB
hyper-editing or COPA hypo-editing, respectively compared
with the matched NT liver specimens (FLNB: p<0.0001;
COPA: p<0.0001; paired Student’s t test) (ﬁgure 4C,D).
Consistently, FLNB hyper-editing and COPA hypo-editing were
found in approximately 49% (23/47) and 74% (35/47) of the
HCC cases in the SH cohort, respectively (FLNB: p<0.0001;
COPA: p<0.0001; paired Student’s t test) (ﬁgure 4C,D).
We conclude that as a consequence of the differentially
expressed ADARs (ADAR1 and ADAR2), HCC displays a dis-
rupted A to I editing balance, which was reﬂected by the altered
gene speciﬁc editing patterns.
ADAR1 has oncogenic ability, while ADAR2 functions as a
tumour suppressor gene
As upstream regulators of A to I RNA editing, ADAR proteins
have a number of reported target transcripts, such as serotonin
receptor subunit 2C (5-HT2CR), glutamate receptor (GluRs),
ﬁlamin A (FLNA) and bladder cancer associated protein
(BLCAP).17 21 22 This prompted us to study the functional roles
of ADAR1 and ADAR2 during hepatocarcinogenesis. For this
purpose, we introduced ADAR1 (p110) or ADAR2 expression
constructs into two HCC cell lines (SNU-423 and SNU-449)
expressing the relative low endogenous ADAR1 (p110) and
ADAR2 among six HCC cell lines using a lentiviral system
(ﬁgure 5A,B). As detected by in vitro functional assays, cells
transduced with the ADAR1 lentivirus (423-AR1 and 449-AR1)
had accelerated growth rates and higher frequency of focus for-
mation than cells transduced with the control LacZ lentivirus
(423-LacZ and 449-LacZ) (ﬁgure 5C and see online supplemen-
tary ﬁgure S4A). However, introduction of ADAR2 into
SNU-423 and SNU-449 cells (423-AR2 and 449-AR2) could
effectively inhibit tumorigenic abilities, including signiﬁcant
inhibition of cell growth rate and reduction in frequency of
focus formation (ﬁgure 5C and see online supplementary ﬁgure
S4A). Consistent with the clinical correlation between tumour
recurrence and the differentially expressed ADAR1 and ADAR2
in tumours, 449-AR1 and 449-AR2 cells demonstrated
increased and decreased migrative and invasive capabilities,
respectively, compared with 449-LacZ cells (ﬁgure 5D,E). As
expected, this phenotype could also be observed in 423-AR1
and 423-AR2 cells compared with control cells (see online sup-
plementary ﬁgure S4B,C). Xenograft studies in mice demon-
strated that the growth rate of tumours induced by 449-AR1 or
449-AR2 cells was markedly higher or lower, respectively, than
those induced by 449-LacZ cells (ﬁgure 5F,G). All of these data
demonstrate that ADAR1 and ADAR2 have the opposite effects
on tumorigenicity. ADAR1 has oncogenic ability while ADAR2
functions as a tumour suppressor gene, suggesting that there is a
tight link between the unbalanced A to I editing mediated by
the differentially expressed ADARs and HCC initiation and
progression.
DISCUSSION
The data from our transcriptome measurement demonstrate dif-
ferentially expressed gene proﬁling and reveal multiple types of
SNVs. These variants are expected to consist of (in descending
order of frequency) inherited polymorphisms, somatic
mutations, sequencing errors and actual differences between
RNA and DNA (eg, RNA editing and polyadenylation). RNA
editing is broadly deﬁned as the post-transcriptional process that
alters the sequence of primary RNA transcripts. Of the various
types of RNA editing, A to I (G) modiﬁcation is most wide-
spread in higher eukaryotes.18 23 24 The most frequent RNA
editing mechanism in mammals involves the conversion of spe-
ciﬁc adenosines into inosines by the ADAR family of enzymes.
The majority of A to I substitutions occur not within coding
portions of mRNA but largely in non-coding RNAs.25 Early
RNA editing studies have revealed that the editing occurs in
many tissues and organs. In humans, this process is thought to
occur predominantly in the brain and may be a key regulator of
neural development. Recent studies have demonstrated that
altered RNA editing is associated with numerous human path-
ologies, particularly cancers. Accumulating evidence has indi-
cated that a hypo-editing phenotype is found in brain tumours
and tumour tissues, such as prostate, lung, kidney and testis;
additionally, the hypo-editing phenotype is linked to several
cancer phenotypes in paediatric astrocytomas and malignant
gliomas.17 26 27
Recent studies have revealed that the developmental and cell
type speciﬁc modulation of A to I RNA editing is linked to
ADAR expression and localisation.19 It has been reported that
all of the three editing enzymes, ADAR1, ADAR2 and ADAR3,
were found to be downregulated in brain tumours. Consistently,
overexpression of ADAR1 and ADAR2 in the U87 glioblastoma
multiforme cell line resulted in a decreased proliferation rate,
suggesting that the reduced A to I editing in brain tumours is
involved in the pathogenesis of cancer.17 In contrast, ADAR1
and/or ADAR2 were found to be upregulated in tumour tissues,
such as prostate cancer and breast cancer tissues.28 Similar to
many other solid tumours, HCC development is believed to be
a multistep process involving the accumulation of genetic and
epigenetic alterations.7 8 However, the role of RNA editing in
HCC progression remains unknown. In this study, we identiﬁed
an average of 20 007 A to I RNA editing events in transcripts.
Intriguingly, unlike most types of cancers that are associated
with a general decrease or increase in RNA editing activity,
HCC is neither a hypo- nor hyper-editing cancer and displays a
disrupted A to I editing balance in coding regions and non-
coding Alu repetitive elements in human HCC. Moreover, the
connection between the differential expression of ADARs and
an altered gene speciﬁc editing pattern was investigated for the
ﬁrst time to illustrate how the A to I RNA editing balance was
deregulated in HCC. Based on RNA-Seq transcript quantitation,
the highest transcript abundance of ADAR1 was found in liver
tissue whereas ADAR2 was expressed at extremely low levels,
and ADAR3 was undetectable in all samples. Most ADAR pro-
teins localise to the nucleus, with the exception of the ADAR1
p150 isoform which is shuttled between the nucleus and cyto-
plasm and is thought to be responsible for the A to I editing of
the viral RNA produced by viruses in the cytoplasm of infected
cells.18 20 In this study, we revealed that both of the ADAR1
p110 and p150 variants were overexpressed in approximately
70% of the primary HCC samples whereas ADAR2 was down-
regulated in approximately 50% of HCC cases. Clinically, the
differentially expressed ADAR1 and ADAR2 in HCC, as shown
by ADAR1 overexpression and ADAR2 downregulation in
tumours, predicts a poor prognosis for HCC patients.
In addition, A to I editing can be very speciﬁc, leading to
deamination of select adenosine residues, or it can be almost
random and lead to non-selective conversion of many inosines.
For long dsRNA (>100 bp) within 30UTR regions, many
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adenosine residues are edited promiscuously, leading to approxi-
mately 50% of adenosines being converted to inosines.
However, in terms of A to I editing of protein coding sequences,
it is highly selective, and an imperfect fold back dsRNA struc-
ture is formed between the exon sequence surrounding the
editing site(s) and a downstream intronic complementary
sequence termed editing site complementary sequence.24
As described in our recent study, the AZIN1 transcript under-
goes A to I editing by a similar mechanism involving the fold
back dsRNA structure conﬁgured from complementary edited
exon 11 and the downstream 100 bp intronic sequences.12 In
addition, ADAR1 has a 50 nearest neighbour preference of
Figure 5 ADAR1 (Adenosine DeAminase that acts on RNA 1) has oncogenic ability while ADAR2 functions as a tumour suppressor gene. (A)
Relative ADAR1 p110 and ADAR2 expression levels in six hepatocellular carcinoma cell lines, as detected by quantitative real time PCR (mean±SD of
three independent experiments). (B) Western blotting showing expression of ADAR1 p110 and ADAR2 proteins in the indicated cell lines. β-Actin
was the loading control. (C) Quantiﬁcation of foci formation induced by the indicated stable cell lines. Triplicate independent experiments were
performed and the data were expressed as the mean±SD of triplicate wells within the same experiment (unpaired two tailed Student’s t test). Scale
bar 1 cm. (D, E) Quantiﬁcation of cells from the indicated cells that invaded through the Matrigel coated membrane (D) or migrated through the
polyethylene terephthalate membrane (E) (unpaired two tailed Student’s t test). Scale bar 200 μm. (F) Growth curves of tumours derived from the
indicated cell lines over a period of 8 weeks. Data are presented as mean±SD (unpaired two tailed Student’s t test). (G) Volumes of tumours derived
from the indicated cell lines at the end point. Data are presented as mean±SD (unpaired two tailed Student’s t test). *undetectable.
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A=U>C>G but no reported 30 nearest neighbour preference.29
On the other hand, ADAR2 has a 50 nearest neighbour prefer-
ence of A≈U>C=G and 30 nearest neighbour preference of
U=G>C=A.30 In this study, two representative recoding editing
events at codon 164 (Ile→Val) of the COPA gene and codon
2269 (Met→Val) of the FLNB gene were selected for further
study. The overexpression and knockdown/rescue experiments
demonstrated that FLNB editing was catalysed by both ADAR1
and ADAR2 and that COPA editing was speciﬁcally catalysed by
ADAR2. Intriguingly, two individual cohorts of HCC samples
displayed signiﬁcantly higher and lower editing levels of FLNB
and COPA, respectively, compared with matched NT liver
tissues. Moreover, the altered gene speciﬁc editing activities
were closely associated with HCC pathogenesis from normal to
adjacent non-tumour to clinically veriﬁed HCC. To our knowl-
edge, unlike the editing events that occur within 30UTR regions,
where the editing can affect transcript stability via affecting
microRNA targeting or the nuclear retention of transcripts,
those within coding regions will cause amino acid change and
affect protein function rather than protein level. Similar to the
FLNB transcript, AZIN1 is one of the recoding editing targets
that are placed in the ‘common editing events’ category. As a
result of the A to I editing of AZIN1 transcripts, the serine
(S)→glycine (G) substitution at residue 367, located in β strand
15 (β15) and predicted to cause a conformational change,
induced a cytoplasmic to nuclear translocation and conferred
gain of function phenotype. Moreover, AZIN1 editing was cata-
lysed by ADAR1, and an 18% increase in AZIN1 editing fre-
quency was sufﬁcient to promote tumorigenic phenotypes,12
strongly suggesting there exists a causative relationship between
the altered RNA editing activity and HCC progression. ADAR1
and ADAR2 proteins have numerous editing substrates;
although it is tempting to investigate if the editing alterations in
the speciﬁc genes analysed may be relevant to the malignant
phenotype, studying the functional connection between the
decreased/increased expression of ADARs and carcinogenesis is
of extreme biological importance. Here, our functional studies
have indicated that ADAR1 has oncogenic ability while ADAR2
functions as a tumour suppressor gene. Therefore, we propose a
model in which the precise regulation of the expression levels of
ADARs is essential for accurate editing, and the altered expres-
sion of ADARs could be at the origin of cell transformation.
Investigating the connection between RNA editing and
cancer progression is only the initial step in this research. Recent
efforts to identify RNA editing events in the human transcrip-
tome using deep sequencing approaches have indicated that
many of the identiﬁed RNA–DNA differences could be explained
by errors in sequencing or mapping errors in the assignment of
RNA-Seq reads to the reference transcriptome.31–33 Moreover,
most recoding sites may be modiﬁed only to levels of less than
a few percent.19 In this study, we reported two recoding
editing events with high level modiﬁcation rates. Speciﬁcally,
FLNB editing could be detected in nearly all of the primary
HCC samples. More importantly, as a result of the differen-
tially expressed ADARs (ADAR1 and ADAR2) in tumours,
alterations in the gene speciﬁc editing activities are closely asso-
ciated with HCC pathogenesis. Therefore, we speculate that
monitoring expression levels of ADARs or the global activity of
RNA editing represents a useful early biomarker for the detec-
tion of disorders in HCC before clinical symptoms become
apparent. Generation of in vivo models for gene speciﬁc
editing deﬁciency or hyper-editing should better elucidate the
physiological signiﬁcance of particular editing events in the
context of liver cancer.
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